morn summari compil research report summari comment publish roth capit pleas click headlin
comment access copi full research report includ applic disclosur
effort improv curat gain traction- highlight lifecor valu
upgrad buy lift price target upgrad base sever item
turnaround cost program substanti chang cost structur announc
strateg altern veggi busi improv margin reduc volatil increas
valuat new manag creat cultur continu improv turnaround
abl separ curat lifecor unlock valu activist investor like
keep pressur execut
rais estim reiter buy reed ginger launch show strong initi
accept offer signific stock/estim upsid option simultan core brand
reed virgil outperform growth assumpt releas preliminari result
ahead consensu expect reed full-year guidanc reiter showcas solid
coronaviru volume novarti goe hydroxychloroquin
volume continu updat test yesterday total test complet bump
per day daili diseas statist yesterday repres second day
row daili mortal stay dr murray model predict pivot morn
news novarti nvs-nc addit previou commit dose suppli
hydroxychloroquin global compani also commenc placebo-control phase trial
hospit patient demonstr improv outcom read thought
soon-to-start trial
dial-in acromegali call mycapssa game-chang
dial-in expert call seri touch perspect patient provid
commerci us april acromegali guru dr susan samson guid us specif
factor critic provid switch patient ssa mycapssa dissect key
import disclosur regul ac certif locat end report
apr servic sector overview
apr industri sector overview
technolog sector overview roth
game-chang patient
apr sustain sector overview
catalyst-rich nash liver
may kol new nash get
caught latest develop
dr juan fria
game-chang patient
catalyst-rich nash live
dr harrison
pediatr gh defici pghd dr ron
game-chang patient
catalyst-rich nash liver
diseas management
may kol unlock potenti
ckd stroke dr
may kol new nash get
caught latest develop
dr eric lawitz
bridg treatment gap multipl
bridg treatment gap multipl
pleas contact salesperson
takeaway follow sisco patient-focus drug develop meet fda may hear chma commerci
game plan mycapssa may
inmb describ immin phase trial newli hospit patient aschoff ph
inmb provid addit detail plan begin phase trial administ dn-tnf therapi patient pulmonari
complic infect trial begin enrol soon possibl specif target patient
admit hospit hypoxia yet requir intens respiratori support therapeut goal reduc need
put patient icu need mechan ventil
internet media dynam environ aftahi
broadli look impact pandem societi last day evalu number sourc
data point within internet broader digit economi broad conclus analysi context
bodi report howev caveat remain fluiditi situat much depend abund test
dynam open broader economi
mark thermal imag could bright economi tri reopen aftahi
near-term global economi tri reopen believ thermal imag could area extrem focu enterpris
retail workplac govern entiti venu gener thermal imag foolproof especi asymptomat covid
individu mean help mitig fever enter premis use third-parti thermal camera believ
mark develop compel ai solut issu current tested/impl client
announc scott pittman resign senior vice presid chief offic pursu interest mr pittman departur
relat disagr compani matter relat oper polici practic intend conduct
search fill vacanc temporarili assign author cfo stephani carn control patrick graham
senior director corpor financ serv primari investor contact
move less day move neutral white
less day share increas approxim market agre theme focus natur ga
weight name environ crude oil sever challeng appar market recogn high qualiti
properti manag team post flawless execut record multipl year move higher occur
increas trade volum
april urg announc close small busi paycheck protect program loan provid oper
updat addit highlight number posit develop uranium sector result reiter buy rate
price target
busi servic sector overview roth research analyst jeff martinapril et pt registr requir
page
